OliX Pharmaceuticals has announced the start of a Phase 1 clinical trial for its RNAi therapeutic, OLX72021, which is being developed to treat male-pattern baldness. The study will assess the drug's safety, tolerability and pharmacokinetics in single intradermal injections in up to 30 healthy males with androgenic alopecia over an eight-week period. Participants will be split into five cohorts a..
French company Valneva has released positive results from a Phase III study of its chikungunya vaccine candidate VLA1553, following Merck's exit from the race earlier this year. The vaccine showed a 28-day seroprotection rate of 98.9% in participants given the inoculation, according to results published in medical journal The Lancet. However, more than half of those vaccinated developed at least..
Kymera Therapeutics, a clinical-stage biopharmaceutical company, has released updated clinical data from the phase 1 trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413. The new data shows that both programs continue to demonstrate substantial target knockdown in ongoing clinical trials with no dose limiting toxicities observed. Kymera is developing these drugs to target protein degrada..